As the market finds itself in the thick of Q2 earnings season, there is—per usual—a considerable amount of noise. Companies that have handily beaten consensus expectations have been punished, while others have seen their shares surge despite dramatically missing analyst forecasts.
But as unpredictable as the market’s reaction to some earnings can be, others have been painfully predictable. That has been especially true for telehealth platform Hims & Hers Health (NYSE: HIMS).
